Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
PNAS Nexus ; 1(2): pgac067, 2022 May.
Article in English | MEDLINE | ID: mdl-36713328

ABSTRACT

The new variant of concern (VOC) of SARS-CoV-2, Omicron (B.1.1.529), is genetically very different from other VOCs. We compared Omicron with the preceding VOC Delta (B.1.617.2) and the wildtype (wt) strain (B.1) with respect to their interactions with the antiviral interferon (IFN-alpha/beta) response in infected cells. Our data indicate that IFN induction by Omicron is low and comparable to the wt, whereas Delta showed an increased IFN induction. However, Omicron exceeded both the wt and the Delta strain with respect to the ability to withstand the antiviral state imposed by IFN-alpha.

2.
J Biol Chem ; 295(41): 13958-13964, 2020 10 09.
Article in English | MEDLINE | ID: mdl-32587093

ABSTRACT

The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of the devastating COVID-19 lung disease pandemic. Here, we tested the inhibitory activities of the antiviral interferons of type I (IFN-α) and type III (IFN-λ) against SARS-CoV-2 and compared them with those against SARS-CoV-1, which emerged in 2003. Using two mammalian epithelial cell lines (human Calu-3 and simian Vero E6), we found that both IFNs dose-dependently inhibit SARS-CoV-2. In contrast, SARS-CoV-1 was restricted only by IFN-α in these cell lines. SARS-CoV-2 generally exhibited a broader IFN sensitivity than SARS-CoV-1. Moreover, ruxolitinib, an inhibitor of IFN-triggered Janus kinase/signal transducer and activator of transcription signaling, boosted SARS-CoV-2 replication in the IFN-competent Calu-3 cells. We conclude that SARS-CoV-2 is sensitive to exogenously added IFNs. This finding suggests that type I and especially the less adverse effect-prone type III IFN are good candidates for the management of COVID-19.


Subject(s)
Antiviral Agents/pharmacology , Betacoronavirus/drug effects , Interferon Type I/pharmacology , Interferons/pharmacology , Animals , Betacoronavirus/isolation & purification , Betacoronavirus/physiology , COVID-19 , Cell Line , Chlorocebus aethiops , Coronavirus Infections/pathology , Coronavirus Infections/virology , Humans , Janus Kinases/metabolism , Nitriles , Pandemics , Pneumonia, Viral/pathology , Pneumonia, Viral/virology , Pyrazoles/pharmacology , Pyrimidines , Severe acute respiratory syndrome-related coronavirus/drug effects , Severe acute respiratory syndrome-related coronavirus/physiology , SARS-CoV-2 , Signal Transduction/drug effects , Vero Cells , Virus Replication/drug effects , Interferon Lambda
3.
Front Microbiol ; 10: 272, 2019.
Article in English | MEDLINE | ID: mdl-30853949

ABSTRACT

Acinetobacter baumannii is one of the leading causes of nosocomial infections in humans. To investigate its prevalence, distribution of sequence types (STs), and antimicrobial resistance in cattle, we sampled 422 cattle, including 280 dairy cows, 59 beef cattle, and 83 calves over a 14-month period. Metadata, such as the previous use of antimicrobial agents and feeding, were collected to identify putative determining factors. Bacterial isolates were identified via MALDI-TOF/MS and PCR, antimicrobial susceptibility was evaluated via VITEK2 and antibiotic gradient tests, resistance genes were identified by PCR. Overall, 15.6% of the cattle harbored A. baumannii, predominantly in the nose (60.3% of the A. baumannii isolates). It was more frequent in dairy cows (21.1%) than in beef cattle (6.8%) and calves (2.4%). A seasonal occurrence was shown with a peak between May and August. The rate of occurrence of A. baumannii was correlated with a history of use of 3rd generation cephalosporins in the last 6 months prior to sampling Multilocus sequence typing (Pasteur scheme) revealed 83 STs among 126 unique isolates. Nine of the bovine STs have previously been implicated in human infections. Besides known intrinsic resistance of the species, the isolates did not show additional resistance to the antimicrobial substances tested, including carbapenems. Our data suggest that cattle are not a reservoir for nosocomial A. baumannii but carry a highly diverse population of this species. Nevertheless, some STs seem to be able to colonize both cattle and humans.

4.
Article in English | MEDLINE | ID: mdl-26520020

ABSTRACT

Cation exchange chromatography (CEX) is an integral part of many downstream processes for monoclonal antibodies (mAbs). However, in some cases CEX methods with standard mobile phase conditions do not lead to a sufficient removal of soluble antibody aggregates. The addition of neutral polymers such as polyethylene glycol (PEG) to the mobile phase can improve the separation of proteins in IEC remarkably. The applicability of this solvent modulation technique is limited by protein precipitation at higher PEG concentrations. To overcome this limitation solubility enhancers like polyols and amino acids can be added to the mobile phase. These additives are known to inhibit PEG-induced protein precipitation in solution. This new solvent modulation strategy was tested with three different mAbs on two different CEX resins in the presence of PEG in combination with various solubility enhancers. In order to assess the general applicability of this method, mAbs were selected that show major differences with respect to their sensitivity to PEG-induced precipitation and monomer/aggregate resolution performance that is achieved by CEX under standard conditions. For all three mAbs precipitation could be prevented without elimination of the positive PEG-effect. The addition of solubility enhancers gives access to improved separation at elevated PEG concentrations and high protein loadings without running into precipitation issues. Our data indicate that this method is generically applicable and leads to a superior antibody monomer/aggregate separation.


Subject(s)
Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/isolation & purification , Chromatography, Ion Exchange/methods , Solvents/chemistry , Polyethylene Glycols/chemistry , Solubility , Sorbitol/chemistry
5.
Vet Radiol Ultrasound ; 55(6): 592-8, 2014.
Article in English | MEDLINE | ID: mdl-24798796

ABSTRACT

Diffusion-weighted imaging (DWI) MRI has been primarily reported as a method for diagnosing cerebrovascular disease in veterinary patients. In humans, clinical applications for diffusion-weighted MRI have also included epilepsy, Alzheimer's, and Creutzfeld-Jakob disease. Before these applications can be developed in veterinary patients, more data on brain diffusion characteristics are needed. Therefore, the aim of this study was to evaluate the distribution of diffusion in the normal canine brain. Magnetic resonance imaging of the brain was performed in ten, clinically normal, purpose-bred beagle dogs. On apparent diffusion coefficient maps, regions of interest were drawn around the caudate nucleus, thalamus, piriform lobe, hippocampus, semioval center, and cerebral cortex. Statistically significant differences in mean apparent diffusion coefficient were found for the internal capsule, hippocampus, and thalamus. The highest apparent diffusion coefficient (1044.29 ± 165.21 µm(2)/s (mean ± SD (standard deviation)) was detected in the hippocampus. The lowest apparent diffusion coefficient was measured in the semioval center (721.39 ± 126.28 µm(2)/s (mean ± SD)). Significant differences in mean apparent diffusion coefficients of the caudate nucleus, thalamus, and piriform lobe were found by comparing right and left sides. Differences between brain regions may occur due to differences in myelination, neural density, or fiber orientation. The reason for the differences between right and left sides remains unclear. Data from the current study provide background for further studies of diffusion changes in dogs with brain disease.


Subject(s)
Brain/anatomy & histology , Diffusion Magnetic Resonance Imaging/veterinary , Dogs , Animals , Female , Male , Prospective Studies , Reference Values
6.
J Sep Sci ; 35(22): 3130-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23111946

ABSTRACT

Ion-exchange chromatography is used in biopharmaceutical downstream processes to reduce product-related impurity levels. Because protein aggregate levels can be considered as a critical quality attribute, the removal of aggregated protein species is of primary importance. The addition of polyethylene glycol (PEG) to the mobile phase in ion-exchange chromatography was found to significantly improve the chromatographic separation of monomers from aggregates. In this work, linear gradient elution experiments with monomeric and aggregated samples of a monoclonal antibody were performed on a strong cation exchange resin at different PEG concentrations to investigate the underlying effects responsible for the observed selectivity improvement. PEG is well known to be excluded from a surface layer volume around the protein and the stationary phase; thus, enhancing adsorption of the preferentially hydrated protein to the hydrated stationary phase. The exclusion volume depends on the accessible surface area of the protein leading to a stronger influence of PEG on larger protein species and thus an improved separation of monomer and aggregates. This hypothesis could be consolidated comparing the distribution equilibrium in PEG solution to that in water by calculating equilibrium constants and transfer free energies using the chromatographic data from the linear gradient elution experiments performed at different pH values.


Subject(s)
Antibodies, Monoclonal/isolation & purification , Cation Exchange Resins/chemistry , Chromatography, Ion Exchange/methods , Adsorption , Antibodies, Monoclonal/chemistry , Chromatography, Ion Exchange/instrumentation , Polyethylene Glycols/chemistry
7.
J Biol Chem ; 286(22): 19501-10, 2011 Jun 03.
Article in English | MEDLINE | ID: mdl-21460230

ABSTRACT

Insulin-like growth factor I (IGF-I) has important anabolic and homeostatic functions in tissues like skeletal muscle, and a decline in circulating levels is linked with catabolic conditions. Whereas IGF-I therapies for musculoskeletal disorders have been postulated, dosing issues and disruptions of the homeostasis have so far precluded clinical application. We have developed a novel IGF-I variant by site-specific addition of polyethylene glycol (PEG) to lysine 68 (PEG-IGF-I). In vitro, this modification decreased the affinity for the IGF-I and insulin receptors, presumably through decreased association rates, and slowed down the association to IGF-I-binding proteins, selectively limiting fast but maintaining sustained anabolic activity. Desirable in vivo effects of PEG-IGF-I included increased half-life and recruitment of IGF-binding proteins, thereby reducing risk of hypoglycemia. PEG-IGF-I was equipotent to IGF-I in ameliorating contraction-induced muscle injury in vivo without affecting muscle metabolism as IGF-I did. The data provide an important step in understanding the differences of IGF-I and insulin receptor contribution to the in vivo activity of IGF-I. In addition, PEG-IGF-I presents an innovative concept for IGF-I therapy in diseases with indicated muscle dysfunction.


Subject(s)
Insulin-Like Growth Factor I/pharmacokinetics , Muscle, Skeletal/metabolism , Musculoskeletal Diseases/drug therapy , Polyethylene Glycols/pharmacokinetics , Receptor, Insulin/agonists , Animals , Cell Line , Dogs , Half-Life , Humans , Hypoglycemia/chemically induced , Hypoglycemia/metabolism , Insulin-Like Growth Factor Binding Proteins/metabolism , Insulin-Like Growth Factor I/chemistry , Insulin-Like Growth Factor I/pharmacology , Muscle, Skeletal/pathology , Musculoskeletal Diseases/metabolism , Musculoskeletal Diseases/pathology , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacology , Receptor, Insulin/metabolism
8.
Mol Cell Neurosci ; 19(4): 528-38, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11988020

ABSTRACT

We identified a population of mature sympathetic neurons in which Ret, the receptor for glial cell line-derived neurotrophic factor (GDNF), is coexpressed with the neurotrophin-3 (NT3) receptor TrkC and choline acetyltransferase. In a complementary population the nerve growth factor receptor TrkA is coexpressed with the norepinephrine transporter. In accordance with these in vivo results, GDNF and neurturin promote the expression of cholinergic marker genes in sympathetic chain explants, similar to NT3 and ciliary neuronotrophic factor (CNTF). To define intracellular signaling mechanisms commonly activated by NT3, GDNF, or CNTF to promote cholinergic differentiation, we have analyzed the activation of intracellular signaling cascades. Signal transducer and activator of transcription-3 (STAT3) was strongly activated by CNTF but not by GDNF or NT3 and hence is not essential for cholinergic differentiation. We conclude that cholinergic properties can be regulated by neurotrophic factors from three different protein families, whereas noradrenergic properties are promoted by NGF.


Subject(s)
Acetylcholine/biosynthesis , Cell Differentiation/physiology , Drosophila Proteins , Ganglia, Sympathetic/embryology , Nerve Growth Factor/metabolism , Nerve Growth Factors , Nerve Tissue Proteins/metabolism , Neurons/metabolism , Norepinephrine/metabolism , Protein Serine-Threonine Kinases , Amino Acid Sequence , Animals , Cell Differentiation/drug effects , Chick Embryo , Choline O-Acetyltransferase/metabolism , DNA-Binding Proteins/metabolism , Ganglia, Sympathetic/cytology , Ganglia, Sympathetic/metabolism , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Developmental/physiology , Glial Cell Line-Derived Neurotrophic Factor , Glial Cell Line-Derived Neurotrophic Factor Receptors , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Molecular Sequence Data , Nerve Growth Factor/pharmacology , Nerve Tissue Proteins/pharmacology , Neurons/cytology , Neurons/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-ret , Receptor Protein-Tyrosine Kinases/metabolism , Receptor, trkA/metabolism , Receptor, trkC/metabolism , STAT3 Transcription Factor , Trans-Activators/metabolism , Vasoactive Intestinal Peptide/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...